|
Richard C.E. Morgan is Chief Executive Officer of Amphion Innovations PLC and currently serves as chairman of Axcess International, Inc. (Nasdaq:AXSI), FireStar Software, Inc. , and Motif BioSciences Inc. In addition, he is a member of the boards of Celgene Corporation (Nasdaq:CELG) and WellGen Inc. In the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 30 companies in the information technology, healthcare and biotechnology industries, including: MediSense, Sequus Pharmaceuticals, Celgene, Quidel and Vortech Data. He was a founder and CEO of Amphion Capital Partners LLC and was a founder and CEO of VennWorks LLC. Mr. Morgan is also the managing general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Before joining Wolfensohn, he spent 15 years with the Schroders PLC, most recently as managing director of J. Henry Schroder Wagg and Co. (a British merchant bank), where, as chairman of the Investment Committee, he supervised the management of over $50 billion in investment assets. He was founder and leader of The Schroder Strategy Group, which gave strategic and financial advice to over one hundred corporations around the world . A British citizen, Mr. Morgan was raised in Kenya and educated in England. He graduated with a B. Engineering (First Class Honours) from the University of Auckland, New Zealand and won an Open Scholarship to undertake a two-year postgraduate research program in engineering and material science. In 1982, he completed the Advanced Management Program at the Harvard Business School. | 